Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Attitudes to antipsychotics: a multi-site survey of Canadian psychiatry residents

Attitudes to antipsychotics: a multi-site survey of Canadian psychiatry residents The purpose of this paper is to identify the training needs of the next generation of psychiatrists, and barriers in prescribing first-generation antipsychotics (FGAs), long-acting injectable (LAIs) antipsychotics and clozapine.Design/methodology/approachAn electronic survey was sent to psychiatry residents (N= 75/288, 26 percent) at four Canadian residency programs in late December 2017. The survey was based on an instrument originally developed at the University of Cambridge and consisted of 31 questions in 10 content domains.FindingsNearly 80 percent of residents were aware that FGAs and second-generation antipsychotics (SGAs) have similar efficacy. However, extra-pyramidal symptoms and lack of training experience were the leading concerns associated with the prescribing of FGAs. Although over 90 percent of residents felt confident about initiating an oral SGA as a regular medication, only 40 percent did so with FGAs. Confidence with initiating LAIs and clozapine was 60 and 61 percent, respectively.Practical implicationsThe survey highlights the need for better training in the use of FGAs, clozapine and LAIs. These medications can be effectively used in providing patients with the most appropriate evidence-based treatment options to improve treatment outcomes, while ensuring that these resources are not lost to the future generations of psychiatrists.Originality/valueThe survey may be the first of its kind to assess antipsychotic prescribing attitudes in Canadian psychiatry residents in multiple sites. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Mental Health Training, Education and Practice Emerald Publishing

Attitudes to antipsychotics: a multi-site survey of Canadian psychiatry residents

Download PDF
21 pages

Loading next page...
 
/lp/emerald-publishing/attitudes-to-antipsychotics-a-multi-site-survey-of-canadian-psychiatry-AGUWIU78sx
Publisher
Emerald Publishing
Copyright
© Emerald Publishing Limited
ISSN
1755-6228
DOI
10.1108/jmhtep-03-2018-0019
Publisher site
See Article on Publisher Site

Abstract

The purpose of this paper is to identify the training needs of the next generation of psychiatrists, and barriers in prescribing first-generation antipsychotics (FGAs), long-acting injectable (LAIs) antipsychotics and clozapine.Design/methodology/approachAn electronic survey was sent to psychiatry residents (N= 75/288, 26 percent) at four Canadian residency programs in late December 2017. The survey was based on an instrument originally developed at the University of Cambridge and consisted of 31 questions in 10 content domains.FindingsNearly 80 percent of residents were aware that FGAs and second-generation antipsychotics (SGAs) have similar efficacy. However, extra-pyramidal symptoms and lack of training experience were the leading concerns associated with the prescribing of FGAs. Although over 90 percent of residents felt confident about initiating an oral SGA as a regular medication, only 40 percent did so with FGAs. Confidence with initiating LAIs and clozapine was 60 and 61 percent, respectively.Practical implicationsThe survey highlights the need for better training in the use of FGAs, clozapine and LAIs. These medications can be effectively used in providing patients with the most appropriate evidence-based treatment options to improve treatment outcomes, while ensuring that these resources are not lost to the future generations of psychiatrists.Originality/valueThe survey may be the first of its kind to assess antipsychotic prescribing attitudes in Canadian psychiatry residents in multiple sites.

Journal

The Journal of Mental Health Training, Education and Practice – Emerald Publishing

Published: Nov 14, 2018

Keywords: Training; Education; Schizophrenia; Drug therapy

References

  • Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth
    Abidi, S.; Mian, I.; Garcia-Ortega, I.; Lecomte, T.; Raedler, T.; Jackson, K.; Pringsheim, T.; Addington, D.
  • Clozapine: a friend estranged?
    Agarwal, M.; Rao, N.P.; Venkatsubramanian, G.
  • A study of attitude and knowledge of the psychiatry resident doctors toward clinician-pharmaceutical industry interaction
    Balhara, Y.P.S.; Mathur, S.; Anand, N.
  • Why are long-acting injectable antipsychotics still underused?
    Bosanac, P.; Castle, D.J.
  • [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]
    Bret, P.; Bret, M.-C.; Queuille, E.
  • Treatment of schizophrenia
  • Clozaphobia: fear of prescribers of clozapine for treatment of schizophrenia
    Cetin, M.
  • An updated clozapine treatment guide against clozaphobic attitudes
    Cetin, M.; Kose, S.
  • First-generation antipsychotics: not gone but forgotten
    Dibben, C.R.M.; Khandaker, G.M.; Underwood, B.R.; O’Loughlin, C.; Keep, C.; Mann, L.; Jones, P.B.
  • Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review
    Fickweiler, F.; Fickweiler, W.; Urbach, E.
  • Barriers to utilizing long-acting injectable antipsychotic medications
    Getzen, H.; Beasley, M.; D’Mello, D.A.
  • IBM SPSS Statistics for Macintosh
  • Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists
    Jaeger, M.; Rossler, W.
  • Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?
    Jauhar, S.; Guloksuz, S.; Andlauer, O.; Lydall, G.; Marques, J.G.; Mendonca, L.; Dumitrescu, I.; Roventa, C.; De Vriendt, N.; van Zanten, J.S.; Riese, F.; Nwachukwu, I.; Nawka, A.; Psaras, R.; Masson, N.; Krishnadas, R.; Volpe, U.
  • Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
    Jones, P.B.; Barnes, T.R.E.; Davies, L.; Dunn, G.; Lloyd, H.; Hayhurst, K.P.; Murray, R.M.; Markwick, A.; Lewis, S.W.
  • Clozapine: a distinct, poorly understood and under-used molecule
    Joober, R.; Boksa, P.
  • Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine
    Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H.
  • Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis
    Kirschner, M.; Theodoridou, A.; Fusar-Poli, P.; Kaiser, S.; Jäger, M.
  • Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility
    Koranek, A.M.; Smith, T.L.; Mican, L.M.; Rascati, K.L.
  • CATIE and CUtLASS: can we handle the truth?
    Lewis, S.; Lieberman, J.
  • Pharmaceutical industry sponsorship and research outcome and quality: systematic review
    Lexchin, J.; Bero, L.A.; Djulbegovic, B.; Clark, O.
  • Dopamine targeting drugs for the treatment of schizophrenia: past, present and future
    Li, P.; Snyder, G.L.; Vanover, K.E.
  • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K.
  • Importance of patient pressure and perceived pressure and perceived medical need for investigations, referral, and prescribing in primary care: nested observational study
    Little, P.; Dorward, M.; Warner, G.; Stephens, K.; Senior, J.; Moore, M.
  • Long-acting injectable antipsychotics: evidence of effectiveness and use
    Manchanda, R.; Chue, P.; Malla, A.; Tibbo, P.; Roy, M.-A.; Williams, R.; Iyer, S.; Lutgens, D.; Banks, N.
  • Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample
    Park, S.-C.; Lee, M.-S.; Kang, S.-G.; Lee, S.-H.
  • Qualtrics survey platform
  • Guidelines for the pharmacotherapy of schizophrenia in adults
    Remington, G.; Addington, D.; Honer, W.; Ismail, Z.; Raedler, T.; Teehan, M.
  • Clinicians’ attitudes toward the use of long-acting injectable antipsychotics
    Samalin, L.; Charpeaud, T.; Blanc, O.; Heres, S.; Llorca, P.-M.
  • The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials
    Schott, G.; Pachl, H.; Limbach, U.; Gundert-Remy, U.; Ludwig, W.-D.; Lieb, K.
  • Physician motivations for nonscientific drug prescribing
    Schwartz, R.K.; Soumerai, S.B.; Avorn, J.
  • Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in São Paulo, Brazil
    Silveira, A.S.D.E.A.; Rocha, D.M.L.V.; Attux, C.R.D.E.F.; Daltio, C.S.; Silva, L.A.d.A.; Elkis, H.; Kane, J.M.; Bressan, R.A.
  • Long-acting injectable Risperidone for relapse prevention and control of Breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial
    Subotnik, K.L.; Casaus, L.R.; Ventura, J.; Luo, J.S.; Hellemann, G.S.; Gretchen-Doorly, D.; Marder, S.; Nuechterlein, K.H.
  • Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US food and drug administration database
    Turner, E.H.; Knoepflmacher, D.; Shapley, L.
  • Consistency of atypical antipsychotic superiority to placebo in recent clinical trials
    Woods, S.W.; Stolar, M.; Sernyak, M.J.; Charney, D.S.
  • Influence of medical representatives on prescribing practices in Mekelle, Northern Ethiopia
    Workneh, B.D.; Gebrehiwot, M.G.; Bayo, T.A.; Gidey, M.T.; Belay, Y.B.; Tesfaye, D.M.; Kassa, T.T.